The University of Zimbabwe College of Health Sciences (UZ-CHS) BIRTH COHORT study: rationale, design and methods. by Duri, Kerina et al.
STUDY PROTOCOL Open Access
The University of Zimbabwe College of
Health Sciences (UZ-CHS) BIRTH COHORT
study: rationale, design and methods
Kerina Duri1* , Felicity Z. Gumbo2, Privilege T. Munjoma1, Precious Chandiwana3, Kudakwashe Mhandire4,
Asaph Ziruma5, Andrew Macpherson6, Simbarashe Rusakaniko7, Exnevia Gomo3,8, Benjamin Misselwitz6†,
Lovemore Ronald Mazengera1† and the UZ-CHS Birth Cohort Team
Abstract
Background: Commencing lifelong antiretroviral therapy (ART) immediately following HIV diagnosis (Option B+),
has greatly improved maternal-infant health. Thus, large and increasing numbers of HIV-infected women are on ART
during pregnancy, a situation concurrently increasing numbers of HIV-exposed-uninfected (HEU) infants. Compared
to their HIV-unexposed-uninfected (HUU) counterparts, HEU infants show higher rates of adverse birth outcomes,
mortality, infectious/non-communicable diseases including impaired growth and neurocognitive development.
There is an urgent need to understand the impact of HIV and early life ART exposures, immune-metabolic
dysregulation, comorbidities and environmental confounders on adverse paediatric outcomes.
Methods: Six hundred (600) HIV-infected and 600 HIV-uninfected pregnant women ≥20 weeks of gestation will be
enrolled from four primary health centres in high density residential areas of Harare. Participants will be followed up
as mother-infant-pairs at delivery, week(s) 1, 6, 10, 14, 24, 36, 48, 72 and 96 after birth. Clinical, socio-economic,
nutritional and environmental data will be assessed for adverse birth outcomes, impaired growth, immune/
neurodevelopment, vertical transmission of HIV, hepatitis-B/C viruses, cytomegalovirus and syphilis. Maternal urine,
stool, plasma, cord blood, amniotic fluid, placenta and milk including infant plasma, dried blood spot and stool will
be collected at enrolment and follow-up visits. The composite primary endpoint is stillbirth and infant mortality
within the first two years of life in HEU versus HUU infants. Maternal mortality in HIV-infected versus -uninfected
women is another primary outcome. Secondary endpoints include a range of maternal and infant outcomes. Sub-
studies will address maternal stress and malnutrition, maternal-infant latent tuberculosis, Helicobacter pylori
infections, immune-metabolomic dysregulation including gut, breast milk and amniotic fluid dysbiosis.
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Discussion: The University of Zimbabwe-College of Health-Sciences-Birth-Cohort study will provide a
comprehensive assessment of risk factors and biomarkers for HEU infants’ adverse outcomes. This will ultimately
help developing strategies to mitigate effects of maternal HIV, early-life ART exposures and comorbidities on infants’
mortality and morbidity.
Trial registration: ClinicalTrial.gov Identifier: NCT04087239. Registered 12 September 2019.
Keywords: Perinatal HIV/ART exposures, Breastfeeding, Maternal comorbidities, Immune-metabolic dysfunction,
Microbiota dysbiosis, Adverse birth outcomes, Neonatal/infant/childhood adverse outcomes, Resource limited
setting
Background
Zimbabwe, a land-locked country in Southern Africa, is
enduring a generalised human immunodeficiency virus
type 1 (HIV-1) epidemic since 1985 [1]. With a popula-
tion of 16 million, 1.3 million people were living with
HIV-1 in 2016, of these, 200,000 were children under
the age of 15 [2]. Like any other sub Saharan African
(SSA) country, Zimbabwe is confronted with concomi-
tant epidemics of HIV-1, co-infections [3–11] and non-
communicable diseases (NCDs) such as cardiovascular
diseases and metabolic syndromes [12–15]. Furthermore,
SSA infants and their mothers are exposed to malnutri-
tion [16] and poor access to clean water, sanitation and
hygiene [17, 18].
The introduction of antiretroviral therapy (ART) in
SSA has greatly improved maternal-infant health (2;19;
20). In 2013, Zimbabwe adopted the Option B+ strategy
of commencement of lifelong ART immediately follow-
ing HIV diagnosis. With ART and even worse without
treatment, HIV-1 exposure is associated with adverse
birth outcomes and HIV-infected pregnant women have
higher rates of stillbirths, preterm births and deliveries
of low birth weight infants compared to their HIV-
uninfected counterparts [19–25].
ART has greatly improved the outcome of infants with
HIV-1 exposure. Without treatment, 31% of HIV-
infected mothers transmitted the virus to their infants
by 6 months of age and most infants progressed to ac-
quired immunodeficiency syndrome (AIDS) rapidly, with
only 50% surviving beyond the age of two [26]. ART has
reduced mother to child transmission (MTCT) of HIV-1
to less than 1% in developed countries, and greatly im-
proved infant survival [27]. In Zimbabwe, the Option B+
strategy decreased HIV-MTCT rate to 3.6% in 2014 [28].
In spite of these benefits, concerns have been raised
on the growing numbers of HIV-1 exposed uninfected
(HEU) infants not achieving comparable health out-
comes relative to their HIV-1 unexposed uninfected
(HUU) counterparts. HEU infants were more likely to
experience growth failure [29–32] and had 1.5-fold
higher rates of hospitalisations and 2–3.9-fold higher
mortality rates, mostly due to infections [33–37].
Neurodevelopmental outcomes were also worse in HEU
children [38], possibly due to exposures to other mater-
nal infections during pregnancy [39, 40] including co-
infection with cytomegalovirus (CMV) [41–44].
Antiretroviral drugs can accumulate in the amniotic
fluid [45], possibly explaining some adverse outcomes on
foetal [46–48] and infant development [49–52]. Dolute-
gravir is slowly being introduced into clinical practice in
SSA. However, it has been associated with a high risk of
preterm delivery (31.6%) and birth defects [53, 54].
HEU infants show aberrations of the immune system
at birth [55–57] with systemic immune activation [56,
58] which could be linked to adverse health outcomes
[59, 60]. HEU infants also have lower antibody titres fol-
lowing vaccination [61, 62] with abnormal B- and T-
lymphocyte phenotypic profiles [63, 64]. It is therefore
unclear, whether HEU infants are able to mount protect-
ive lifelong responses to all vaccines promoted via the
national Expanded Program of Immunization (EPI,
Table 1).
Taken together, the health of the large and ever grow-
ing population of HEU infants is a great public health
concern in SSA. There is a complex interplay of
maternal-infant HIV and coinfections, ART exposures,
immune dysregulation, NCDs and low socio-
demographic status associated with food insecurity and
poor sanitation. While individual risk factors have been
Table 1 The extended program of vaccination (EPI)
Age Vaccine
At Birth BCG, (hepatitis b to be introduced soon)
6 weeks Pentavalent 1, OPV1, pneumococcal 1, rotavirus 1,
10 weeks Pentavalent 2, OPV2, pneumococcal 2, rotavirus 2,
14 weeks Pentavalent 3, OPV3, IPV, pneumococcal 3,
9 months Measles and rubella,
18 months DTP, OPV booster, measles and rubella.
EPI was established by the WHO in 1974 to develop and expand immunization
throughout the world. The Zimbabwe vaccination schedule is indicated. In
addition, Vitamin A supplementation is given from 6months of age and
thereafter every 6months until 5 years. Pentavalent: Diphtheria, Pertussis,
Tetanus, Hepatitis B and Haemophilus influenzae type B. IPV inactivated
poliovirus vaccine, OPV Oral polio vaccine, DTP Diphtheria, BCG
Bacillus Calmette–Guérin
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well characterized, there is a need to analyse these pa-
rameters in a large comprehensive prospective analysis
combining deep clinical, socio-demographic and envir-
onmental assessment with extensive bio-sampling, im-
proving the detection of adverse health outcomes. In
Zimbabwe, HEU infants have been well-studied during
the pre-ART and monotherapy eras [37, 65]. However,
contemporary evidence is lacking. We hereby introduce
the University of Zimbabwe College of Health Sciences
(UZ-CHS) Birth Cohort Study, aiming to address these
challenges.
Methods
Aim of the study
This study aims to identify predictors for short- and
long-term adverse infant outcomes in a resource limited
setting. We will examine the impact of maternal HIV in-
fection and comorbidities, cumulative ART exposure in
utero and throughout the breastfeeding period, including
the effects of maternal immune suppression, immune ac-
tivation and environmental variables.
Our study is focusing on mortality and morbidity of
HEU infants, testing established risk factors from previ-
ous cohorts done during the pre-ART and monotherapy
eras. Data and biomaterials will be collected prospect-
ively from mothers and infants from enrolment at ≥20
weeks of gestation to 2 years after birth to enable captur-
ing of infant development.
Objectives and outcomes
Primary outcomes:
 The primary outcome of this study is the frequency
of stillbirth as well as perinatal and postnatal
mortality until two years of age of HEU infants
versus HUU infants in a multivariable analysis
controlled for confounders.
 Maternal mortality from enrolment until two years
after delivery in HIV-infected versus HIV-uninfected
participants in a multivariable analysis controlled for
confounders.
Secondary outcomes of our study include a range of
maternal, birth and infant outcomes summarized in
Table 2.
Study setting
The University of Zimbabwe College of Health Sciences
(UZ-CHS) Birth Cohort study is a prospective observa-
tional cohort study comparing infants born to HIV-
infected and HIV-uninfected women in a resource lim-
ited setting of Western high-density suburbs of Harare
attending Municipal primary health polyclinics. One
thousand two hundred (1200) pregnant women (600
HIV-infected mothers and 600 HIV-uninfected controls)
at ≥20 weeks of gestation will be enrolled from February
2016 to June 2019. Participants will be followed as
mother-baby pairs (MIPs) at birth, within 10 days of life
and at 6, 10, 14, 24, 48, 72 and 96 weeks of age.
Questionnaires will be administered and bio-samples
for laboratory tests will also be acquired at each visit.
Biomaterials will be acquired for specific tests including
tests for infections, clinical biochemistry, full blood
counts and immune status, dysbiosis (Tables 3). In
addition, at each study visit maternal-infant clinical ex-
aminations will be done and used to assess health status
including the impact of household and environmental
factors. The study will be a non-interventional cohort
study design, but participants will be offered health care
and health education.
Study sites, local municipal engagement and routine
clinical care
The Municipality of Harare has established 12 poly-
clinics each comprising units for primary health care,
maternity, post-natal care and a family health service.
Medical services include HIV counselling and rapid test-
ing including initiation and administration of ART.
Monitoring and follow-up for other chronic conditions
including diabetes mellitus and arterial hypertension are
also offered. A physician comes twice a week per site to
attend to complicated cases. Maternity services comprise
antenatal care, postnatal care, treatment of hypertensive
disorders, HIV and syphilis screening and treatment.
For each pregnant woman, routine lab results and
management prior to enrolment into the study are well
documented in antenatal booklets during routine clinical
care. The study team will have access to these clinical
data during and after the enrolment visit. The standard
of care for all Zimbabwean HIV-infected women to pre-
vent HIV-MTCT consists of (non)–nucleoside reverse
transcriptase inhibitors; TENOLAM-E (Tenofovir, Lami-
vudine and Efavirenz, and to breastfeed as long as they
choose to. Exclusive breast-feeding is encouraged during
the first six months of life, with breastfeeding along with
appropriate complementary foods up to 2 years of age or
even older. According to Zimbabwean national guide-
lines, all HIV-infected women should be on Option B+,
but in practice women often do not receive a timely HIV
diagnosis.
Independent from our study, all infants including
HIV-1 exposed and infected (HEI) infants, are moni-
tored for growth, and also receive vaccination as shown
in Table 1 as per the Zimbabwean EPI program. Clinic
visits for any ailments are managed at a local primary
health centre with complicated cases being appropriately
referred to the nearest tertiary hospital. All HIV exposed
infants are tested for HIV by reverse transcriptase
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polymerase chain reaction (RT-PCR) (Table 3, point ii.)
at birth, 6 weeks of age and after cessation of breast
feeding. Upon detection of HIV infection, infants are im-
mediately commenced on ART, usually comprising the
protease inhibitors Lopinavir/ritonavir and the nucleo-
side reverse transcriptase inhibitors; Zidovudine and
Lamivudine. In addition, all HIV exposed infants are
commenced on Cotrimoxazole prophylaxis until they
stop breast feeding or they test HIV RT-PCR positive,
whichever occurs first.
It costs a pregnant woman United States (US)
twenty-five dollars ($25) to access antenatal services
until six weeks after delivery whilst health care ser-
vices are free of charge for infants until 5 years of
age. They are encouraged to book early during
pregnancy (at week 4–12 gestational age) and to test
for HIV together with their spouses/partners. Cur-
rently, due to social-economic challenges, most Zim-
babwean pregnant women go for antenatal
registration at the polyclinics when their pregnancies
are at advanced stages, a situation that puts their un-
born babies at risk for HIV transmission, perpetuating
the vicious cycle of poverty and HIV infections.
Following a pre-study site feasibility assessment in
September 2015, out of the 12 polyclinics, Kuwad-
zana, Dzivaresekwa (Rujeko), Glenview and Budiriro
in South West of Harare city centre were selected
based on the higher volumes of maternal and child
health services, frequency of HIV positivity and lack
of competing research activities targeting the same
Table 2 Secondary outcomes of UZ-CHS Birth cohort study
Secondary outcomes
1. Comparison of morbidity of HEU vs. HUU infants, defined as impaired growth, immune- and neuro-development and/ or frequent of clinically rele-
vant infections.
2. To determine any association of ART exposure in utero and during breast feeding with pregnancy outcome, infant (HUU, HEU, HEI) growth and
immune- and neuro-development.
3. To determine vertical transmission rates for HIV at birth and within the first 2 years of life and assess risk factors for transmission.
4. To determine the association between maternal baseline and delivery ART levels in different compartments and infant HIV infection, mortality and
morbidity.
5. To determine HIV drug resistance profiles in mother and infants unresponsive to ART.
6. To assess abnormalities including lipid profiles, bone, haematological and hepatic toxicities associated with exposure to ART among mothers and
infants.
7. To determine antenatal co-infections including HBV, HCV, CMV, syphilis, intestinal helminths and parasites as single infection or combined infections
in HIV-infected and HIV -uninfected - women and determine the impact on pregnancy outcome, infant mortality and morbidity.
8. To determine the prevalence of infant infectious comorbidities; HBV, HCV, CMV, syphilis, including time points of infections and impact on
mortality and morbidity.
9. To determine the prevalence of maternal NCDs (malnutrition/ obesity, anaemia, diabetes, hypertensive disorders) and determine their impact on
pregnancy outcomes, infant mortality and morbidity.
10. To determine infant non-infectious comorbidities (e.g. anaemia, atopic dermatitis, congenital infections and other conditions) and their impact on
mortality and morbidity.
11. To determine maternal household non-biological factors (socioeconomic state, hygiene) and determine their impact on pregnancy outcome, in-
fant mortality and morbidity.
12. To determine antenatal reference ranges for MUAC, haemoglobin from FBC analyses, and biochemistry (kidney function, liver function tests, bone,
lipid profiles) in pregnant women with a favourable outcome of pregnancy.
13. To assess delayed neurological development using the Denver II tool in HUU, HEU and HEI infants from 6 weeks to 2 years of age.
14. To determine humoural immune responses to EPI vaccines (e.g. antibody levels against measles, tetanus, diphtheria, pertussis, polio and rotavirus)
in HUU, HEU and HEI infants.
15. To determine maternal intestinal parasites load using 18S sequencing in pregnancy and relate it to infant immune development and atopy (anti-
inflammatory (IL-4, − 5, − 13) and regulatory cytokines (IL-10, TGF-β) at delivery, 6 weeks 48 and 96 weeks of age.
16. To determine immune activation and systemic inflammatory biomarkers in HUU, HEU and HEI infants at delivery, 6, 48 and 96 weeks of age.
17. To determine biomarkers for endothelial dysfunction including microbial translocation in HUU, HEU and HEI infants at delivery, 6, 48 and 96 weeks
of age.
18. To determine host genetic markers for infectious disease susceptibility including HLA and KIR gene variants and their association with infection
rates of HIV and co-infections in mothers and their infants.
19. To characterize pathogen genetic diversity including HIV, HBV, HCV, CMV subtypes, prevalent in our study population at time of infection/ earliest
available samples and/or at 2 years.
ART antiretroviral therapy, CMV cytomegalovirus, FBC full blood count, HBV hepatitis B virus, HCV hepatitis C virus, HLA human leukocyte antigen, HIV human
immune deficiency virus, HEI HIV exposed and infected, HEU HIV exposed but uninfected, HUU: HIV unexposed and uninfected, IL interleukin, KIR killer
immunoglobulin like receptor, MUAC mid upper arm circumference, NCD non-communicable diseases, TGF transforming growth factor
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Table 3 Summary of the tests done in mothers and infants at different time points
Assessments Method/threshold value(s) Equipment/ kits/comment
HIV-1/2 diagnosis:
All HIV uninfected women at enrolment and every
6 months.
All HIV exposed infants from 18months of age
Qualitative rapid immunochromatographic, whole
blood serial testing algorithm according to the
national guidelines for HIV testing and counselling
[66].
- Initial screening; SD Bioline HIV-1/2 3.0 (Standard
Diagnostics Inc., Kyonggi-do, South Korea.
-Confirmation; Alere Determine™ HIV-1/2 (Abbott
-Diagnostics, Lake Bluff, USA).
-Tie breaker; Western blotting, The Orasure kit,
Epitope Inc., USA
Early infant HIV diagnosis:
All HIV exposed infants from delivery, at every visit
until weaning or diagnosis of HIV infection up to
18 months of age [67].
HIV-1 RNA Qualitative Test on dried blood spots
(DBS), according to the manufacturer’s instructions.
COBAS1 AmpliPrep/ COBAS1 TaqMan1 HIV-1 RNA
Qualitative Test (Roche Molecular System Inc.,
Branchburg, NJ, USA.
HIV-1 RNA quantification:
In plasma, of all HIV infected women at enrolment
and exit
In BM colostrum, and every 6 months
All HIV infected infants’ earliest positive DBS
sample and at exit
According to the manufacturer’s recommendations.
The lower detection limit of the assay; 20 copies/
mL
Automated TaqMan Roche Amplicor 1.5 Monitor
Test (Cobas AmpliPrep/Cobas TaqMan, Roche
Diagnostics, Branchburg NJ, USA.
Immune status assessment:
All HIV infected women at enrolment and exit
All HIV infected infants earliest positive whole
blood sample and at exit
CD4 + T-lymphocyte (absolute) count EDTA whole
blood sample
CD4+ T-lymphocyte (percentage).
Partec Cyflow counter (Munster, Germany) be
performed within 6 h of whole blood collection.
Maternal ART levels:
Efavirenz, Lamivudine, Tenofovir will be tested
enrolment, and every 12 months in all mothers on
ART
Different compartments, plasma, breast milk, urine
and amniotic-fluid as previously described [68].
Agilent Technologies, Palo Alto High performance
liquid chromatography, Agilent 6430 Triple
Quadrupole LC-MS/MS system, CA, USA.
Syphilis serology:
All mothers at enrolment and exit
All exposed infants from delivery and at every visit
HBV/HCV serology:
All mothers at enrolment and exit
All exposed infants from delivery and at every visit
(DBS)
HBV DNA Assays:
Host genetics of HBV infection susceptibility
CMV serology:
All mothers at enrolment and exit
CMV DNA test:
All mothers at enrolment and exit
All exposed infants from delivery and at every visit
(DBS)
Host genetics of CMV infection/ transmission
Detection of anti-Treponema pallidum antibodies
and a non-Treponemal slide agglutination test for
the semi-quantitative detection of plasma reagins
in serum.
HBsAg detection,
Profiling; HBsAg, HBsAb, HBeAg, HBeAb & HBcAb
Plasma, breast milk HBV
DNA for occult hepatitis determination
HBV plasma DNA levels
HLA, KIR typing (whole blood)
CMV IgG, IgM levels, avidity assays.
CMV DNA in plasma, amniotic fluid breast milk and
urine
CMV DNA in DBS
HLA, KIR typing
Qualitative rapid immunochromatographic and, SD
Bioline 3.0, SD Biosensor, Korea
Fortress diagnostics Ltd., UK
Screening; SD Bioline, Korea
Confirmation; Quality kit, USA
Tie breaker: Acon, USA
HBV profile All positives: 5 profile (CTK, USA)
HBV TaqMan PCR Kit, Norgen Biotek, Norway
COBAS1 AmpliPrep/ COBAS1 TaqMan1 HBV DNA
Quantitative Test (Roche Molecular System Inc.,
Branchburg, NJ, USA
As previously described (112).
PerkinElmer kits, Euroimmun, South Africa
RealStar CMV PCR kit v1.0 (Altona Diagnostics,
Hamburg, Germany), following isolation of viral
DNA using the QIAamp MinElute Virus Spin Kit
(Qiagen, Hilden, Germany).
As previously described [69].
Clinical biochemistry:
All mothers serum at enrolment and exit
All infants serum within, 6 and 24 months of age
Renal; creatinine, urea, uric acid, Urinary protein and
albumin eGFR [70].
Liver enzymes
Including AST, GGT, bilirubin, LDH, ALP,
Cardiac markers; troponin CKMB. Lipids; total and
LDL/HDL cholesterol. Bone profile; calcium,
magnesium, phosphate.
Beckman Coulter AU680 chemistry analyser (Krefeld,
Germany)
Urinalysis strips, Cypress Diagnostics. HELLP
syndrome for acute kidney injury assessment
LDH: AST ratio > 22 distinguishing TTP from HELLP
syndrome. Keiser SD [71]. All results to determine
antenatal reference ranges associated favourable
outcome of pregnancy
Full blood counts:
All mothers at enrolment and exit
All infants within 10 days of life, 6 and 24 months
of age
Maternal haemoglobin concentration < 11.0 g/dl
and, and varying with age for infants, < 13.5 g/dl)
within the first month of life and < 10.7 g/dl from 9
weeks of age [72].
Mindray© Haematology 3-part differential, 16 pa-
rameters BC3600 Analyser (Shenzhen, China)
Determine antenatal reference ranges associated
favourable outcome of pregnancy
Maternal blood random glucose and HbA1c:
Once in pregnancy at enrolment
Cut off values for random glucose of 110 mg/dl
(6.1 mmol/L) within 2 h of a meal or 101 mg/dl (5.6
mmol/L) more than 2 h postprandial. A cut off for
HbA1c of 6.5% will identify undiagnosed diabetes
mellitus whilst an HbA1c ≥5.6% will mark
individuals with an increased risk for future diabetes
[73].
Mindray BS200 Chemistry Analyser (Mindray,
Shenzen, China)
Determine antenatal reference ranges associated
favourable outcome of pregnancy
Intestinal pathogens:
All mothers at enrolment and exit
All Infants at exit
Maternal and infant stool samples will be screened
for, H pylori, intestinal protozoa and helminths
trophozoites and ova.
Direct wet mount microscopy and the formal-ether
concentration technique [124].
Humoural immune responses to EPI vaccines
Infants At 6 weeks, 12 and 24 months of age
Antibody titres EPI will be measured [74, 75]. The Bio-Plex® 200 system Luminex analyser, Bio-
Rad, CA, USA
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Table 3 Summary of the tests done in mothers and infants at different time points (Continued)
Assessments Method/threshold value(s) Equipment/ kits/comment
Plasma inflammation and cell stress
biomarkers:
In a subgroup of MIPs with different durations of
exposures to ART from pregnancy to 12 months of
age
At least 25 inflammatory chemokines and cytokines
measurements.
The Bio-Plex® 200 system Luminex analyser, Bio-
Rad, CA USA
Plasma metabolomics:
> 400 analytes, in a subgroup of MIPs with
different durations of exposures to ART from
pregnancy to 12 months of age to assess altered
amino acid and lipid metabolism
3 platforms
-Biogenic amines (Amino acids, catecholamines &
polyamines), Signalling lipids (Sphingosine-1-
phosphate etc., Positive lipids (Lysophospholipids,
phospholipids, cholesterol esters, di/triglycerides &
sphingomyelins) as described [76].
UPLC; TQMS; QToF –HPLC; UHPLC –; MS/MS – Triple
Quadrupole Mass Spectrometer.
Infants atopic sensitization
Infant blood samples from 6, 24 and 96 weeks.
Total and specific serum IgE against food/aero-
allergens will be assessed in selected Infants with
specific serum IgE levels > 0.3 IU/mL will be
considered sensitised [77, 78].
Immuno-assay analyser (Thermofisher, Freiburg,
Germany).
Breast milk characterisation
Maternal milk from delivery up to weaning time
Micro−/macronutrients, vitamins, oligosaccharides,
immunological biomarkers, essential fatty PUFAs
such aslinoleic acid and α-linolenic acid: precursors
of LCPUFA e.g. arachidonic acid and docosohexaa-
noic acid, from birth until weaning [79].
Gas chromatography, GC-CP3800, Varian, USA)
equipped with a flame ionization detector and a
fused silica capillary column 50 m × 0.25 mm (I.D.
CP-SIL 88 for FAME), Pennsylvania (PA) 16,823–0048,
USA).
Lab based Sub studies assessments
Plasma inflammatory biomarkers
In a subgroup of MIPs from pregnancy,
breastfeeding period and after weaning
−7 panels, including cytokines, chemokines,
vascular injury, angiogenesis, Th17.
V-PLEX Human Biomarker 54-Plex Kit, ECL Technol-
ogy, Maryland, USA.
Multiplexed 16S sequencing
In a subgroup of MIPs from pregnancy,
breastfeeding period and after weaning
16S rRNA gene segment spanning V5 and V6
regions in stool, plasma and breast milk as
previously described [80].
Illumina MiSeq/Ion Torrent PGM sequencer.
Breast milk (whole) immune-metabolomics
In MIPs with adverse outcomes, from colostrum,
and at least 3 later points.
Non-targeted injection analysis. Mass spectrometry (TQF-MS), Agilent 6550, Agilent
Technologies Inc., Santa Clara, CA.
Maternal mycotoxins biomarkers
In pregnancy, at delivery and exit
Level of mycotoxin biomarkers including aflatoxins
B1 and 2 in urine, amniotic-fluid and milk
Measurement will be performed on Agilent 6430
Triple Quadrupole LC-MS/MS system, Palo Alto, CA,
USA
Natural killer (NK) cells characterisations
In a subgroup of HEU (with short, medium and
long term ART exposures) versus HUU infants two
time points between 12 and 24 months of age.
NK cells surface marker staining: CD2, CD3, CD16,
CD56, CD69, KIR and mitochondria functional assays
following PBMC isolation, including nutrient
transporter expression on NK cells: Glut1, CD98, and
CD71. Mitochondrial function of NK cells will be
done using mitotracker green and mitotracker deep
red assays.
The BD LSR Fortessa™ cell analyser, multicolour (16
colour) flow cytometer assays, BD Sciences
Maternal latent TB testing:
In a subgroup of HIV infected and uninfected in
pregnant women and 6 weeks postpartum
CD4/CD8 IGRAs against TB antigens (ESAT-6/CFP-
10/TB-7.7 against TST/ Mantoux at 0.1 ml dose.
Qiagen QuantiFERON gold plus kit, USA, Tuberculin
purified protein derivative (PPD) Mantoux,
TubersolR, Sanofi Pasteur, in tween solution, 5 US
units per test
Salivary cortisol levels
In a subgroup of MIP at 6 months follow up visit
Test done according to the manufacturer’s
recommendations. Sensitivity is 0.007μg/dl.
Salimetrics, LLC competitive enzyme immunoassay
kit, Carlsbad, CA USA.
Helicobacter pylori testing
In a subgroup of MIP from pregnancy to exit
Quantitative ELISA; H. pylori IgG IgA, IgM antibodies
and detection of H pylori antigens from birth to 24
months according to the manufacturer’s
recommendations H pylori Ag Sensitivity:0.165 ng/
ml.
Sandwich enzyme Immunoassay, Colorimetric test
ELISA, Monobind Lake Forest, CA USA.
ALP alkaline phosphatase, AST aspartate aminotransferase, BM breast milk, CD cluster of differentiation, CK-MB creatine kinase-myocardial band, CMV
cytomegalovirus, EPI expanded program for immunization, GC gas chromatography, GGT gamma-glutamyl transferase; Glut1 glucose transporter-1,
HbA1c glycosylated haemoglobulin, HBcAb hepatitis B core antibody, HBeAb hepatitis B e-antibody, HBeAg hepatitis B e-antigen, HBsAb hepatitis B
surface antibody, HBsAg hepatitis B surface antigen, HBV hepatitis B virus, HCV hepatitis C virus, HDL high density lipoprotein, HEI HIV exposed infected,
HELLP haemolysis, elevated liver enzymes and low platelet count, HEU HIV exposed but uninfected, HIB Haemophilus influenza type b, HIV human
immunodeficiency virus, HLA human leukocyte antigen, HPLC high-pressure liquid-chromatography, HUU HIV unexposed and uninfected, IGRAs
interferon gamma release assays, KIR killer cell immunoglobulin-like receptor, LCPUFA long chain poly unsaturated fatty acids, LDH lactate
dehydrogenase, LDL low density lipoprotein, MIPs mother-infant pairs, MS mass spectrometer, PUFA poly unsaturated fatty acids, QToF quad time of
flight, TB tuberculosis, TQMS triple quadrupole mass spectrometer, TST tuberculin skin test, TTP thrombotic thrombocytopenic purpura, UHPLC ultra-
high-pressure liquid-chromatography, UPLC ultra-pressure liquid-chromatography
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population. The catchment areas of the selected four
polyclinics have relatively stable communities that do
not frequently change their rented accommodation.
For this study, Municipal midwives at the selected fa-
cilities will assist with sample/data collection for de-
liveries that will occur late at night.
Background characteristics of study participants
All participants reside in South-Western high-density
areas of Harare. Residents of this community are of rela-
tively poor socio-economic status with high unemploy-
ment rates. Most households generally cannot afford 3
decent meals per day. Most families (72%) live on less
than 1 dollar per day [81] and supplement their diet
through small scale vegetable gardening around their
houses. Families live in houses of similar structure and
size (200 m2). On average 2–6 families live in these rela-
tively small houses and in some extreme situations up to
5 family members share a single room. Water supply is
erratic, necessitating the use of communal boreholes at
200–1500metres distance. This manually fetched water
is used for drinking, cooking, bathing and flushing of
toilets. Sewage bursts are common and may occur close
to these boreholes. Contaminated boreholes in two of
our four study sites, Budiriro and Glenview, have been
epicentres of the 2018 cholera epidemics [7]. Residents
of these high-density residential areas share a dispropor-
tionate burden of infectious diseases relative to those liv-
ing in low-density areas in the same city.
Study participants
UZ-CHS birth cohort study enrolled consenting preg-
nant women registering for antenatal care at any of the
4 selected City of Harare polyclinics. Upon delivery, ba-
bies will be automatically recruited into the study and
followed up as MIPs for two years. In cases of multiple
births (twins or triplets) all infants of the recruited
mother will be followed. Follow up is feasible and rela-
tively easy in Zimbabwe where about 90% of pregnant
women own or have access to a mobile phone [82].
Inclusion and exclusion criteria
Pregnant woman of Bantu origin should be ≥15 years of
age, at least 20 weeks of gestation at enrolment and
planning to deliver at any of the 4 study sites. Due to
the current economic challenges, nearly all pregnant
women in high-density areas in Harare present to Muni-
cipal health clinics at or beyond 20 weeks of pregnancy.
Therefore, no upper limit for gestational age for inclu-
sion applies, to ensure a representative study population.
All pregnant women with a documented positive HIV
status will be encouraged to enrol in the study. For every
HIV-infected pregnant woman recruited, the 10th HIV-
uninfected woman presenting to the same primary
health clinic for the initial antenatal registration will be
recruited, accounting for the 12% HIV prevalence within
this population. The pregnancy will be dated by the
standard way of using menstrual history together with
ultrasound scans whenever available as documented in
the antenatal booklet which is routinely issued to all
pregnant women. Mothers should be willing to be
followed together with their babies from delivery, and
willing to provide the required data and biological speci-
mens in follow-up visits for two years. Exclusion criteria
will be the presence of severe maternal mental health
disorders, rendering the women incapacitated to provide
informed consent or comply with study procedures as
assessed by the study Clinicians.
Sample size and statistical power
The composite primary endpoint of our study is the
comparison of stillbirths and mortality in HEU versus
HUU children until two years of age. In Zimbabwe, in-
fant mortality rates of 50 per 1000 live births in the first
year and 5 deaths per 1000 live infants in the second
year of life are expected. In the pre-ART era, a 3.2–3.9-
fold higher mortality in the first year of life and a 2-fold
higher mortality in the second year of life was observed
[37, 83]. Mortality of HEU in the Option B+ era with
more effective HIV treatment might now be improved
and in a conservative estimation, we assumed a 2-fold
increase in mortality in HEU infants within the first two
years of life.
We therefore expect 5.5% mortality in HUU infants
and 11% in HEU infants. According to our power ana-
lysis using G*Power3 [84], a sample size of 1198 preg-
nant women will be required to detect such a difference
with a power of 90% and a significance level of 0.05 in a
two-sided analysis. We therefore, will opt for a sample
size of 1200 pregnant women, 600 with and 600 without
HIV infection.
Selection of participants
Potential participants will be identified during routine
antenatal care visits at any of the four selected City of
Harare Polyclinics. The potential participants will be
briefed on the study and those who would have verbally
agreed to participate in the study will be given the par-
ticipant information sheet in the language of their
choice, either in English or vernacular Shona to ensure
full comprehension of the study aims and expected ac-
tivities using the language that the participant under-
stands best. Participation is voluntary and women will
be free to withdraw at any time during the course of the
study. Literacy is nearly universal in Zimbabwe [85] and
all potential participants should be able to read and
comprehend the informed consent form. However, in
cases of illiterate study participants, consent will be
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documented by clearly impressing the right thumbprint
on the signature page of the consent form. The actual
process of right thumb printing will be witnessed by the
study participant’s literate relative of her choice who will
print his or her name on the informed consent form and
will also sign as a witness in the presence of the study
team member.
No payment to research participants is required by
Zimbabwean law and hence no formal payments to par-
ticipants will be made for this study. However, research
participants will be reimbursed US $5 to cover travel ex-
penses at every study visit and offered refreshments dur-
ing the waiting time that will range from 30 to 60min.
The study team will offer health education and counsel-
ling on pregnancy, delivery and childcare on a continu-
ous basis on each study visit.
Mothers’ questionnaires procedures and measurements
A midwife will administer a structured questionnaire to
all pregnant women at enrolment aiming at a compre-
hensive clinical, behavioural and environmental
characterization. Specific questions will address sexual
behaviour and reproductive health issues including sexu-
ally transmitted diseases and contraception use. General
health, health seeking behaviour, maternal stress and
drug/herbal use will be assessed. To address hygiene,
specific questions on sanitation (type and number of toi-
lets, sewage system), drinking water, type of energy used
(indoor pollution), type of floor(s) in the house, number
of rooms used for sleeping by the family and the number
of individuals sharing a single room will be asked. Eco-
nomic information comprising employment status, fam-
ily monthly income, food security, diet, monthly money
set aside for food, healthcare, cooking fuel and savings
will be assessed. Ownership of agricultural land or
household assets including radios, televisions, mobile or
fixed telephones, refrigerators, bicycles, motorcycles or
scooters, and cars will provide additional information re-
garding social economic status. Further questions will
address maternal life style such as alcohol use, smoking,
sleeping habits, physical activities, domestic violence and
support from spouse/partner including knowledge, be-
liefs and practices in relation to patterns of seeking
health care services, see Tables 4 and 5.
In HIV-infected mothers, ART use, regimen and date
for commencement, co-infections and issues related to
HIV status disclosure and stigma will be recorded. The
information will be verified using clinical records in the
maternal antenatal booklet.
A significant fraction of HIV-infected women will be
unaware of their HIV status and therefore will be ART
naïve [86]. In these women, ART will be initiated upon
first presentation at the antenatal clinic, coinciding with
enrolment into our study. Due to the unfortunate
scenario of late antenatal bookings some women will
therefore commence ART late or very late in pregnancy
during labour. However, other women will be on ART
even before conception. This provides the opportunity
to study the impact of different durations of ART expos-
ure (as a continuous variable based on gestational age at
ART initiation) on birth and infant outcomes. Other
than the in utero exposure, infants’ exposure to ART will
continue throughout the breastfeeding period since
mothers are encouraged to breastfeed regardless of their
HIV status.
Physical examination
At enrolment, the study midwife will perform a full
physical examination, blood pressure checks, assessment
of oedema and anthropometry. World health organisa-
tion (WHO) clinical staging will be done for all HIV-
infected women. The examination will also include
measurement of symphysis fundal height (SFH) for cal-
culation of gestational age in comparison with last men-
strual period (LMP) that is subject to considerable
margin of error, particularly late in pregnancy. The SFH
will be determined by measuring the distance in centi-
metres (cm) from the pubic symphysis to the highest
part of the uterus.
Assessment of nutritional status will be done using
standard anthropometric indices including body mass
index (BMI). Mid upper arm circumference (MUAC) is
an easy, non-invasive and inexpensive technique in an-
thropometry to detect nutritional status [87]. MUAC is
considered an indicator of the body protein reserves,
and unlike BMI is independent of gestational age [88].
MUAC will be used as an indicator for malnutrition, in-
cluding obesity. Mother’s left arm will be bent at the
elbow at a 90 degree angle, with the upper arm held par-
allel to the side of the body. The upper arm circumfer-
ence will be measured at the mid-point distance
between the bony protrusion on the shoulder (acromion)
and the point of the elbow (olecranon). Previous South
African studies demonstrated that a MUAC of < 23 cm,
predicted a pre-pregnancy BMI of < 18.5 kg/m2 and a
MUAC of > 30.57 cm, predicted a pre-pregnancy BMI of
> 30 kg/m2 [88]. For more practical reasons, a maternal
MUAC cut-offs of ≤25 cm will be used as a marker for
malnutrition. Blood pressure (BP), both systolic and dia-
stolic will be measured after allowing the mother to rest
for at least 5 min.
Maternal and infant follow-up visits
Mothers will be reminded of their upcoming follow-up
study visits by phone call or through text message.
Follow-up will be scheduled at delivery, within 10 days,
6, 10, 14, 24, 36, 48, 72 and 96 weeks postpartum. If a
mother fails to turn up for their scheduled follow-up
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Table 4 Maternal measurements and data collection time points
Variables Research visit (in weeks)
Pregnancy Delivery 1 6 10 14 24 36 48 72 96
A. Maternal life style
1. Current alcohol use ✓ ✓ ✓ ✓
2. Smoking
3. Living under same roof with spouse/partner ✓ ✓ ✓ ✓
4. Current marital/ domestic violence ✓ ✓ ✓ ✓
5. Physical activity ✓ ✓ ✓
B. Household factors
1. Household numbers & composition ✓ ✓ ✓ ✓
2. Number of rooms available ✓ ✓ ✓ ✓
3. Main source of drinking water ✓ ✓ ✓ ✓
4. Main source of energy for cooking (household pollution) ✓ ✓ ✓ ✓
5. Main place for cooking ✓ ✓ ✓ ✓
6. Sleeping arrangements ✓ ✓ ✓ ✓
Water and sanitation ✓ ✓ ✓ ✓
7. Presents of family diarrhoeal diseases ✓ ✓ ✓ ✓
C. Nutritional factors
1. Maternal number of meal a day ✓ ✓ ✓ ✓
2. Household meals eaten per day ✓ ✓ ✓ ✓
3. Food frequency questionnaire ✓ ✓ ✓ ✓
4. Food security tool ✓ ✓ ✓ ✓
5. Perceived food allergens/ adverse reactions ✓ ✓ ✓ ✓
6. 24 h food recall ✓ ✓ ✓
7. Craved foods ✓
8. Any disorder related to food mastication and/ or retention ✓ ✓ ✓ ✓
9. Bristol stool chart ✓ ✓
D. General health
1. Use of condom and sexual behaviour ✓ ✓ ✓ ✓
2. Past and current methods of contraception used ✓ ✓ ✓ ✓ ✓
3. 7Health seeking behaviour ✓ ✓ ✓ ✓
4. Tb symptoms checklist for active Tb ✓ ✓ ✓ ✓ ✓
5. History of Tb disease and treatment ✓ ✓ ✓
6. Current and past other opportunistic infections ✓ ✓ ✓ ✓
7. Past and current symptoms of sexually transmitted infections ✓ ✓ ✓ ✓ ✓
8. Past or current hypertension ✓ ✓ ✓ ✓ ✓
9. Past or current stress ✓ ✓ ✓ ✓ ✓
10. Baby blues assessment tool ✓
11. Depression ✓ ✓ ✓ ✓
12. Hospitalisation in the past 3 months ✓ ✓ ✓ ✓
13. Sick clinic visits during index pregnancy ✓
14. Vaccinations during index pregnancy ✓
15. Timing of antenatal booking, number of subsequent visits ✓
16. Knowledge of pregnancy disorders that warrant immediate hospitalization ✓
17. Concurrent medication and supplements ✓ ✓ ✓ ✓ ✓
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Table 4 Maternal measurements and data collection time points (Continued)
Variables Research visit (in weeks)
Pregnancy Delivery 1 6 10 14 24 36 48 72 96
18. Concurrent herbal and traditional medication ✓ ✓ ✓ ✓ ✓
19. Use of sexual enhancing herbs/ substances ✓ ✓ ✓
20. History of routine dental or pap smear checks ✓ ✓ ✓
21. Anthropometric measurements (BMI, MUAC)) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
22. Systolic and diastolic BP and pulse measurements ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
23. General physical examination (e.g. oedema) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
24. Last date of menstruation
E. HIV-infected only: ART use, duration, disclosure & adherence
1. ART use regimen, duration, switching of regimens ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
2. Presence of adequate supplies ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
3. ART side effects ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
4. Non-adherence issues ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
5. Disclosure of HIV status ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
6. Stigma experience ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
7. WHO clinical staging for the HIV-infected ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
F. Clinical data collected at delivery
1. Mode of delivery ✓
2. Duration of labour ✓
3. Live and stillbirths
4. Term/ preterm delivery
5. Pregnancy outcome ✓
6. Length of stay in hospital/ clinic after delivery ✓
7. Obstetric related complications
8. Time of previous ART intake for HIV-infected mothers ✓
G. Biological specimen collection in the 3rd trimester
1. Stool ✓
i) Intestinal helminths testing
ii) Microbiome profiles (sub-studies)
2. Urine
i) Urinalysis and storage microbiome
✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
3. Blood
i) Serology, molecular genetics, HIV, CMV, HBV, syphilis ✓ ✓
ii) TB QuantiFERON gold (sub-study) ✓ ✓
iii) Full blood counts ✓ ✓
iv) Infant vaccine titres ✓ ✓
v) Biochemistry ✓
a. Dyslipidaemia ✓ ✓
b. Kidney function tests ✓ ✓
c. Liver function tests ✓ ✓
i) Vitamin D ✓ ✓
ii) HbA1c, random glucose ✓
iii) Cytokine profiles ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
iv) CD4 counts ✓ ✓
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appointments, attempts to contact her or her next of kin
by phone and/ or home visits will be made strictly ad-
hering to the documented mother’s preferences. Data
and samples will still be collected provided the missed
visit can be rearranged within the following seven days.
In case of two consecutive missed visits without commu-
nication, study discontinuation will be discussed with
the mother.
Information on place, date and mode of delivery
will be extracted from “Road to Health Child’ cards”
issued at birth for monitoring growth, vaccinations
records until 5 years of age. Longitudinal infant feed-
ing practices and comprehensive information on
health, development and environment will be col-
lected. Extensive questionnaires similar to the one ad-
ministered at enrolment will be re-administered at 6,
12, 18 and 24 months. Physical examinations of
mothers will be performed until week 6 after delivery
and at exit. For infants physical examinations will be
done at every visit. Sick infants will be seen by the
study Paediatrician. Study procedures also include
bio-sampling of blood, breast milk and stool at every
study visit.
Adverse birth outcomes and infant mortality
The key outcome of this study is mortality of infants
assessed by the composite endpoint of stillbirth (gesta-
tional age at birth ≥20 weeks) and infants who die during
the first two years of life.
Adverse birth outcomes will include the need for
resuscitation at birth due to birth asphyxia or respira-
tory distress syndrome. These conditions can be ac-
curately diagnosed by a midwife. Birth asphyxia will
be defined as any medical condition resulting in de-
creased or discontinued supply of oxygen to a new-
born infant before, during or soon after birth. No for-
mal paediatric assessment will be performed at birth;
therefore, accurate diagnosis of other paediatric con-
ditions will not be feasible at this point. Other ad-
verse outcomes at delivery will include preterm birth.
WHO criteria will be applied in calculations regarding
infants’ anthropometric measurements [89]. Gesta-
tional age will be divided into early preterm (20–31
weeks), late preterm (32–36 weeks), term (at least 37
weeks) and post term birth (> 42 weeks of gestation).
Additional adverse outcomes are a low Apgar score at
5 min (< 7), small for gestational age (SGA, i.e.
weight/ length below the 10th percentile for gesta-
tional age), low birth weight (LBW) (< 2500 g,
weighed within the first hour of life, before significant
postnatal weight loss would have occurred), very
LBW (< 1500 g), extremely low birth weight (< 1000
g), foetal macrosomia (birth weight > 4000 g), micro-
cephaly (head circumference < 2 standard deviation
(SD) from the mean) and multiple births. A brief
physical examination will be performed by the mid-
wife regarding structural birth defects (malformations,
e.g. extra digits). All infants with suspicious findings
Table 4 Maternal measurements and data collection time points (Continued)
Variables Research visit (in weeks)
Pregnancy Delivery 1 6 10 14 24 36 48 72 96
v) HIV RNA load ✓ ✓ ✓
vi) CMV DNA load ✓ ✓
vii) HBV DNA load
viii) Host genetic susceptibility ✓
ix) Immunometabolomics ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
H. Delivery bio-specimens
1. Placental pathology in latent Tb (sub-study), microbiome ✓
2. Amniotic-fluid co-infections, alcohol levels, microbiome ✓
3. Breast milk (lipid profiles and microbiome, CMV viral load), microbiome ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
I. Spouse/ intimate partner factors (as reported by mothers)
1. Age ✓
2. Occupation ✓ ✓
3. Previous marital status ✓
4. HIV status, ART usage ✓ ✓
5. Participation in pregnancy, ante ✓ ✓
6. Participation in child care ✓ ✓ ✓
ART antiretroviral therapy, BMI body mass index, CD4 cluster of differentiation-4, CMV cytomegalovirus, EPI The expanded program of immunisation, MUAC mid
upper arm circumference, HbA1c glycated haemoglobin, HBV hepatitis B virus, HCV hepatitis C virus, HLA human leukocyte antigen, HIV human immunodeficiency
virus, KIR killer cell immunoglobulin-like receptor, SGA small for gestational age, TB tuberculosis, WHO world health organisation
Duri et al. BMC Infectious Diseases          (2020) 20:725 Page 11 of 21
regarding birth defects will be followed up by a team
of four board certified study Paediatricians.
Infant growth
Growth will be expressed as Z scores according to
WHO definitions [89]: Weight-for-age (WAZ), height-
for-age (HAZ), weight-for-height (WHZ) and head-
circumference-for-age (HCAZ). Growth outcomes will
be evaluated as continuous variables (attained Z-score
and change in Z-score between visits). In addition, the
following categorical outcomes will be assessed:
– Moderate wasting, WHZ < –2
– Stunting, HAZ < –2
– Severe stunting, HAZ < –3
– Underweight, WAZ < –2
– Microcephaly, HCAZ<-2.
Table 5 Infant data and health assessment tool
Exposure and data collection points (delivery=0 time point) Research visit (weeks)
0 1 6 10 14 24 36 48 72 96
a) Infant in utero exposures
1. HIV exposure in utero/ postpartum ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
2. Antenatal dysbiosis, microbiome ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
3. Congenital co-infections; HBV, HCV, CMV, syphilis ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
4. Alcohol exposure (foetal alcohol syndrome) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
5. Food quantity and quality, antenatal diet, maternal BMI ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
6. Allergens, food, animal dander ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
7. Indoor pollution (paraffin stove cooking in one room/smoker) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
8. Household factors water/sanitation (quantity/quality)/ ✓ ✓ ✓
b) Delivery & Postpartum Data
1. Delivery date, gender, SGA, Apgar score, congenital abnormalities ✓
2. Weight, head circumference and length (MUAC from 6 weeks) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
3. Infant morbidity, sick clinic visits, hospitalisations, atopic dermatitis ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
4. Infant mortality ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
5. EPI immunisation compliance ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
6. Any medication being taken ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
c) Infant developmental assessment tools
1. Denver tool ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
2. Mullen tool (neurodevelopmental sub-study) ✓ ✓ ✓ ✓ ✓
d) Biological specimen collection
1. Cord blood ✓
2. Blood and dried blood spots
a) Vertical transmission of HIV, CMV, HBV, syphilis ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
b) EPI vaccine titres ✓ ✓ ✓ ✓
c) Plasma immune activation biomarkers ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
d) Systemic plasma Inflammation biomarkers and trends ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
e) Endothelial dysfunction biomarkers ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
f) Immunometabolomics ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
g) Biomarkers of intestinal structure and function (permeability, microbial translocation) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
h) Food allergens and atopic dermatitis sensitisation trends ✓ ✓ ✓ ✓
i) Full blood counts and clinical biochemistry ✓ ✓ ✓
j) HIV viral load (in infected individuals) ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
k) Pathogen genetic diversity and Host infection genetics ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
BMI body mass index, CMV cytomegalovirus, EPI The expanded program of immunisation, MUAC mid upper arm circumference, HBV hepatitis B virus, HCV
hepatitis C virus, SGA small for gestational age
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Infant MUAC will be measured from 6weeks of age and
sensitivity, specificity, positive predictive values, and nega-
tive predictive values of the MUAC for stunting, under-
weight, wasting, anaemia and adverse neurodevelopment
in HEI, HEU and HUU infants aged 0- < 6months, 6- <
12months and 12–24months will be determined. WHZ
will be used as the gold standard for wasting.
Assessment of infant morbidity
Morbidity diaries will be issued to mothers at delivery.
Medical professionals unrelated to the study (e.g. Muni-
cipal primary health nurses) will also document medical
reports in the morbidity diary during sick visits and/or
hospitalizations. These will include: neonatal
hypoglycaemia, neonatal jaundice, infant anaemia, skin
rashes, congenital infections, vertical transmission of in-
fections over the 2 years, any hospitalisation (frequency
and duration), sick visits (dates and duration), docu-
mented local inpatient treatments, stunting, wasting and
abnormal neurodevelopment. After episodes of illnesses,
follow up notes will be recorded in the diary by the
study nurse. The mother will also continuously assess
infant well-being and will be encouraged to document
any perceived child sickness in the morbidity diary. Con-
tents of morbidity diaries will captured, pictured/photo-
copied at each study visit.
Infant development
Neurodevelopmental outcomes will be evaluated from
six weeks until two years of age using the Denver II
screening tool [90]. The Denver II tool enables assess-
ment of gross and fine motoric abilities, development of
language, social skills, attention span, general compli-
ance and fearfulness. In addition, infant developmental
milestones (e.g. timing of teething, first sitting, walking
or talking) will be recorded. No neurological assessment
tool has been formally validated in Zimbabwe; the Den-
ver tool will be used since it can be conveniently applied
by the study nurse [90]. Our study Paediatricians’ clinical
experiences indicate that the tool is appropriate without
adjustment for the Zimbabwean setting. For detailed
neurodevelopmental and cognitive assessment, the Mul-
len tool [91] will be used in a sub-study at 12 and 24
months of age.
Maternal biosamples
Biological specimens including whole blood, plasma and
serum, stool, and breast milk will be collected at all
visits; cord blood, amniotic fluid and placenta will be
collected at delivery. Sensitive samples (stool, milk,
urine) will be placed at 4 degree Celsius (°C) for no lon-
ger than 4 h before processing. All samples will be stored
in a bio-bank at − 80 °C within a maximum of 6 h after
acquisition.
Different lab tests will be done (Table 3). Most tests
will apply for all mothers regardless of their HIV status
for comparison of disease burden between both groups.
HIV-uninfected mothers will be continuously coun-
selled and retested for HIV infection every 6months
until 2 years after delivery (Table 3 point i.). Sero-
converting women will be referred to the national HIV
prevention program for immediate commencement of
ART and immunological and virological monitoring.
Infant blood samples
Infant venous blood will be collected whenever possible
at 7–10 days and 24 months for full blood counts.
Whenever possible, plasma samples will be stored. The
volume of blood collected will be within recommended
amounts depending on the weight of the infant (i.e. ≤1–
5% of total blood volume over 24 h and ≤ 10% over 8
weeks) [92]. Blood will not be collected from severely
sick infants and those with suspected severe anaemia ac-
cording to clinical assessment.
Dried blood spots (DBS) will be collected wherever
possible at every visit using whole blood samples or a
needle prick puncture of the heel. 3–5 drops of blood
will be collected and dried on Whatman filter paper and
stored at − 20 °C.
HIV exposed infants will also be tested for HIV within
10 days of life, at weeks 10, 14, 24, 36, 48, 72 and 96 or
until cessation of breast feeding, whichever comes first.
Summary of sub-studies
Gut microbiota sub-study (longitudinal analysis)
Chronic intestinal maladaptive and inflammatory alter-
ations in a resource limited setting with inadequate nu-
trition and hygiene are summarized as environmental
enteric dysfunction (EED). EED is characterized by a de-
layed and aberrant maturation of the intestinal micro-
biota [93, 94], ultimately resulting in dysfunction and
failure of the microbiota metabolic organ [95]. Under-
standing microbiota maturation will likely be key to the
pathogenesis of EED. HIV infection and ART use have
also been associated with a disturbed gut microbiota
[96] and might further aggravate EED.
For in-depth microbiota analysis, sequential stool sam-
ples taken from MIPs will be used to perform 16S rRNA
sequencing for assessment of phylum and operational
taxonomic unit composition with ≥97% sequence iden-
tity, as well as microbial diversity [97]. In selected sam-
ples bacterial full genome metagenomics shotgun
sequencing to identify the microbiota metabolic poten-
tial (i.e. bacterial genes present [96] will be done. Fur-
ther, mass spectrometry will be performed for analysis of
small intestinal content (metabolome) (83;84) including
assessment of markers of microbial translocation across
the damaged gut wall [98] such as lipopolysaccharide
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(LPS), a component of gram-negative bacterial cell walls,
a biomarker of microbial translocation [99], with intes-
tinal fatty acid binding protein (I-FABP) as a biomarker
for enterocyte damage [100]. Continuous passage of
immuno-stimulatory LPS from the intestinal lumen into
the systemic circulation sustains activation of both in-
nate and adaptive immunity causing systemic immune
activation through activation nuclear factor kappa beta
(NF-ϰβ) protein complex that controls transcription of
DNA in cytokine production [101]. Protective factors in-
clude immunoglobulin M (IgM), IgG, and IgA specific
for the LPS core antigen and endotoxin core antibodies
(EndoCAb) [102]. Microbial translocation has been asso-
ciated with HIV clinical progression and early onset of
non-AIDS comorbidities. How microbiota profile is af-
fected by HIV /ART exposures and cotrimoxazole
prophylaxis in settings of poverty and malnutrition re-
mains to be explored with respect to infant growth, de-
velopment and susceptibility to infectious diseases. Use
of probiotics and prebiotics can be potentially used to
modify the disturbed /imbalanced bacterial profile in the
gastrointestinal tract of HEU infants. This microbiota
sub-study will involve sampling of ≥100 women in preg-
nancy and MIPs within 10 days of life, at weeks 6, 10,
14, 24, 36, 48, 72 and 96. Biosamples include MIPs plas-
maand stool samples, including breast milk. See Table 3
xxi, xxii, xxiii and xxiv for details.
Immuno-metabolomics sub-study (longitudinal analysis)
Interference with lipid, glucose amino acids metabolism
is another mechanism for ART toxicity. This sub-study
aims to investigate plasma inflammatory immune activa-
tion markers as risk factors for adverse pregnancy out-
comes in HIV-infected women and subsequent impaired
infant growth and development. For this study-study we
will select a sub group of HIV-infected pregnant women
with long-term (> 7months), medium-term (1–7
months) and no/ short-term (no or < 1 months) ART use
and uninfected women as controls. We will test for sys-
temic inflammatory immune activation markers in
MIPs plasma samples at enrolment, delivery, 10 days, 6,
14, 24, 48 and 72 weeks. Enzyme linked immuno assay
(ELISA)-based multiplex testing by Luminex technology
will be used to measure chemokines and cytokine levels
including, B cell-attracting chemokine 1, brain-derived
neurotrophic factor, interferon gamma inducible protein
10, monokine induced by gamma interferon, monocyte
chemo-attractant protein 1, macrophage inflammatory
protein-1β, tumour necrosis factor alpha, matrix
metalloproteinase-1, transforming growth factor beta,
interferon gamma, interleukin (IL)-1β, IL-2, IL-4, IL-6,
IL-7, IL-10, IL-12, IL12p70, IL-17A, IL-27, INF-γ, cluster
of differentiation (CD) 30 and CD40. See Table 3 xxviii
for details.
To assess the metabolome and mitochondrial dysfunc-
tion, mass spectrometry techniques will be used to
measure a wide range of metabolites including reactive
oxygen species, triglycerides, diacylglycerides, choles-
terol, phospholipids, fatty acids, peroxidized lipids and
oxylipids. Metabolite levels will be correlated to preg-
nancy outcome and with infant growth (LBW, SGA,
stunting wasting) and infants’ immune responses to vac-
cines. This metabolomics component will involve con-
venient sampling of ≥55 women in pregnancy and
respective MIPs within 10 days of life, at weeks 10, 14,
24, 36 and 48. Biosamples include MIPs plasma samples.
See Table 3 xxix for details.
Cell-mediated immunity/ glucose metabolism sub-study
HIV infects activated but not resting CD4+ T-
lymphocytes, and hence the need to understand how
host nucleotide, glucose, lipid, amino acid metabolism
including the respective cell oxidative stress support
HIV RNA replication [103]. Maternal HIV infection and
ART use can cause foetal immune-metabolic dysregula-
tion [104] which may contribute to impaired growth and
long-term abnormal immune development. T-
lymphocyte maturation and natural killer (NK) cell num-
bers or/and functions are altered in HEU new-borns and
these abnormalities persist over time [105–107] causing
increased mortality and morbidity. This sub-study aims
to determine the role of maternal HIV infection on NK
cell surface markers and nutrients transporters expres-
sion of infants with long-term (> 7months), medium-
term (1–7 months) and short-term (< 1months) in utero
ART exposures compared to their HUU counterparts.
We will isolate peripheral blood mononuclear cells
(PBMCs) for cell staining and analysis. Measurements
require samples with sufficient blood volume of ≥2 mL
and hence assays will be done later, after 12 months of
age. We will determine numbers and function of T-
lymphocytes, as well as NK cells as previously described
[108]. This longitudinal sub-study will involve conveni-
ent sampling of ≥160 infants at weeks 48 and 96 of age.
See Table 3 xxvi for details.
Latent tuberculosis co-infection sub-study (longitudinal
analysis)
Co-infection with Mycobacterium tuberculosis (MTB) is
an independent risk factor for maternal mortality in HIV
infection [8]. We hypothesize that undiagnosed latent
TB can partially explain increased infant mortality in re-
source limited settings. Diagnosis of TB can be a clinical
challenge. Sputum tests for TB are generally false-
negative in a significant fraction of patients due low sen-
sitivity [109]. Tuberculin skin test (TST) has been used
to screen for latent TB; however, due to the interaction
with BCG vaccine [110] which is administered routinely
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at birth in Zimbabwe, TST specificity may be greatly
reduced in our study population. To test for latent
TB, IFN-γ release assays (IGRAs), unaffected by BCG
vaccination will be used in a subgroup of HIV- in-
fected and -uninfected women. IGRAs measurements
and size of TST lesions will be correlated with ad-
verse maternal and infant outcomes with the aim to
develop future more sensitive latent TB diagnostic al-
gorithms for pregnant women in resource limited
settings.
This latent TB co-infection sub-study will involve con-
venient sampling of a total of 400 HIV-infected and-
uninfected women. TST will be done in pregnancy and
at 6 weeks postpartum with concurrent collection of
blood for IGRAs testing. Further, placental samples will
be tested for histological lesions suggestive for MTB in-
flammation. Placenta samples will be randomly collected
from ≥100 mothers at delivery. See Table 3 xxvii for
details.
Maternal stress sub-study (longitudinal analysis)
Perinatal stress has been linked to alterations of the
hypothalamic-pituitary-adrenal axis activity of the off-
spring leading to vulnerability later in life. Maternal
stress results in increases in cortisol, norepinephrine and
inflammation with implications in infant health. Causes
of maternal stress include diagnosis of HIV, intimate
partner violence, low socio-economic status, being a sin-
gle parent, unplanned pregnancy, food insecurity includ-
ing bereavement. This sub-study will assess prevalence,
risk factors and coping mechanism of maternal stress
among HIV -infected and -uninfected pregnant women.
In this maternal stress sub-study, a perceived stress tool
will be administered to ≥400 HIV- infected and - unin-
fected women in pregnancy and at 6 weeks postpartum.
Stress hormone, cortisol production has a circadian
rhythm with levels peaking in the early morning and
dropping to the lowest at night, with levels rising inde-
pendently of circadian rhythm in response to stress [111,
112]. Studies have shown high correlations between
serum and salivary cortisol, thus salivary cortisol levels
are a reliable estimate of serum cortisol levels [113]. Sin-
gle salivary cortisol measurement are unreliable as bio-
markers for stress since the circadian rhythm of cortisol
secretion is not captured [114]. We will therefore meas-
ure morning and evening infant saliva cortisol at 6
months of age and correlate levels to child health and
their long term mental health and neurocognitive out-
comes. Infant cortisol levels will be measured in salivary
swabs at week 6 of age. The mothers, following instruc-
tions given by the study nurse will collect the infant sal-
iva swabs for cortisol measurements. See Table 3 xxviii
for test details.
Neurodevelopmental outcomes (longitudinal analysis)
Neurodevelopmental deficits such as language impair-
ment are more severe and more prevalent in HEI and
HEU infants compared with HUU controls in resource
limited settings [115]. This sub-study will be evaluating
potential long-term neurodevelopmental sequelae re-
lated to extended ART exposure. Therefore, a subgroup
of HEU, HEI and HUU infants will have extended test-
ing for cognitive performance and neurodevelopmental
defects using the Mullen tool [91] at 12 and 24months
correlating with socio-economic status and infections. A
total of ≥300 HEU and HUU infants will be conveniently
sampled and followed up.
Immunotoxicology sub-study (longitudinal analysis)
Exposure of pregnant women and their infants to myco-
toxins is a major public health concern, as this may be
associated with nutritional deficiencies and growth re-
tardation. Mycotoxins, especially carcinogenic aflatoxins
b1 (AFB1), produced by Aspergillus flavus are normally
present in poorly stored food grains. Not much has been
done to determine the maternal burden of mycotoxins,
more so in this high HIV prevalence setting. At least in
porcine models exposure to mycotoxin, fumonisin B1
has been shown to alter the immune responses by de-
creasing the level of IL-8 [116].
This sub-study hypothesises that high exposures to
mycotoxin causes maternal immune-dysregulation that
in turn causes adverse birth outcomes and poor infant
health. The main aim is to identity useful biomarkers for
interventions to mitigate mycotoxin exposure associated
adverse birth outcomes and poor health in infants. Ma-
ternal random urine, amniotic fluid and longitudinal
breast milk samples will be analysed for at least 20
mycotoxin biomarkers, including both the parent myco-
toxins and mycotoxin metabolites. High-performance li-
quid chromatography tandem mass spectrometry
method with modifications will be used as previously de-
scribed [117]. A total of ≥400 HIV- infected and -unin-
fected women will be randomly selected in pregnancy,
and followed up at delivery and 24 months after delivery.
Helicobacter pylori sub-study (longitudinal analysis)
The development of chronic gastritis, recurrent peptic
ulcers including gastric cancers has been associated with
H. pylori infections [6]. Risk factors include low socio-
economic status, poor hygiene, and overcrowding [118].
The prevalence of H. pylori infection is persistently
higher in developing countries where more than 70% of
the adult population is colonized with H. pylori, with >
50% children acquiring it by the age of 10 [119]. Most
published data on H. pylori infection are largely centred
on adults. Thus, there are significant knowledge gaps on
the risk factors of initial H. pylori colonization, trends
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and persistence of the infection in children. This sub-
study aims to compare timing and trends of H. pylori
colonisation and immunity among HUU and HEU in-
fants from birth until 2 years of age, with the aim to de-
velop preventive measures to reduce early life infections.
Random sampling of ≥100 women in pregnancy will be
done. Follow up will be within 10 days of life, at weeks
10, 14, 24, 36, 48, 72 and 96 with collection of MIPs
stool samples for testing of H. pylori antigen and anti-
bodies using simple ELISAs. See Table 3 xxix for details.
Study time frame
Pregnant women have been enrolled into the UZ-CHS
Birth Cohort study from February 2016 until June 2019.
MIPs will be followed for 2 years, with an expected study
completion date in June 2021. Long-term follow-up
studies until school-going age and adolescence are in
planning.
Data flow and analysis
Data is being entered at the study sites into paper CRF
that will subsequently be entered into a Research Elec-
tronic Data Capture (REDCap) secure web with regular
backups. Data will be analysed using SPSS (version 17.0,
Chicago, IL) or other analysis tools using standard statis-
tical methods for parametric or non-parametric testing
or analysis of categorical outcomes, whatever
appropriate.
The main endpoint of our study, the composite end-
point of stillbirth and mortality until two years of age of
HEU vs. HUU infants will be corrected for confounders
in a multivariable logistic regression analysis. In this ana-
lysis, we aim to correct for socio-demographic parame-
ters (e.g. maternal age), descriptors of the current and
past reproductive history (e.g. number previous pregnan-
cies, current twin/multiple pregnancy), maternal comor-
bidities (e.g. hypertension, metabolic syndrome,
infectious comorbidities), economic situation (marriage
and employment state, family income), maternal nutri-
tion (e.g. number days without food, MUAC) and hy-
giene (number of days without running water). For
selection of confounders, individual parameters from the
database will be tested in a univariate analysis. If signifi-
cance is detected (p < 0.1), the parameter will be in-
cluded in a multivariable analysis with parameter
elimination for optimization of the Akaike information
criterion. Confounders for maternal outcomes will be se-
lected using a similar strategy.
For secondary outcomes, Cox proportional hazard
models will be used for time-dependent variables, also
controlled for confounders in multivariable analyses.
Predictors of secondary outcomes will also be analysed
using hierarchical all-against-all clustering [120]. A p-
value < 0.05 will be considered significant. We will
provide nominal p-values and Bonferroni-corrected p-
values in case of a multiple testing situation.
Discussion
The UZ-CHS Birth cohort is a prospective study in a re-
source limited setting following up HEU and HUU in-
fants, assessing their health and development within the
first 2 years of life. The composite primary endpoint is
stillbirth and infant mortality within the first two years
of life in HEU versus HUU children. Maternal mortality
from enrolment until two years after birth in HIV in-
fected vs. HIV uninfected participants is another primary
endpoint of this study. Secondary endpoints include a
range of maternal, birth and infant outcomes. It provides
a unique opportunity to answer a multitude of research
questions that build a comprehensive understanding of
the impact of HIV and comorbidities, ART use including
other maternal and infant environmental factors on in-
fant mortality, morbidity, growth and immune/ neurode-
velopment. The potential output will impact on policy
and practice regarding perinatal care for mothers and in-
fants in resource limited settings. The extensive data on
maternal nutrition and hygiene, sexual and reproductive
behaviour, HIV disease characteristics, infectious disease
complications and the extensive bio-sampling of MIPs
provide opportunities for a number of sub-studies to
better understand how environmental exposures modu-
late immune system, microbiota and other physiological
parameters in mothers and their infants.
Health of HEU infants is of great concern and great
public health importance in SSA; however, the reason
for poor outcomes in HEU is not well understood. Be-
sides exposure to HIV and ART, HEU infants might dif-
fer from HUU by exposure to other infections and
maternal co-morbidities and other socio-economic mea-
sures might also differ. For these reasons, a comprehen-
sive study is needed. Results of our analyses might
identify early markers for poor outcome and help to de-
velop specific interventions for HEU infants. For in-
stance, if the response of HEU and HUU infants to
vaccines would differ, the vaccination plan for HEU in-
fants could be modified [121]. On the other hand, the
possibility that exposure to HIV in utero would prime
the immune system with lasting effects after birth war-
rants further studying and could yield in insights regard-
ing immune development.
However, Option B+ strategy does not completely
eliminate MTCT and among the offspring of 600 HIV-
infected mothers, approximately 30 HEI infants are ex-
pected (Fig. 1). Mortality of these infants is expected to
be significantly higher compared to HEU infants, war-
ranting separate analyses of this group for all clinical
analyses and biomarker assays.
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Introduction of ART has dramatically decreased the
MTCT rates by more than 10-fold, an important med-
ical success [2, 122, 123]. However, use of ART in preg-
nancy is a double edged sword and part of the burden
on HEU infants might be due to adverse effects of ART.
The safest ART regimens in pregnancy still needs to be
determined. ART treatment plans continue to evolve
and plans to replace Efavirenz with Dolutegravir are at
an advanced stage but with its challenges [53]. Efavirenz
has been shown to trigger apoptosis, an effect in part
due to interference with mitochondrial membrane po-
tential [48]. Continuous surveillance regarding Dolute-
gravir related structural birth defects can be done in
future sub-studies in our cohort.
Future sub-studies of our cohort might follow infants
into childhood and adolescence to assess long term im-
mune and neurodevelopment including mental health
outcomes. A further desirable future expansion might be
a strictly rural observational cohort, to control for
household, lifestyle and environmental confounders as-
sociated with the current urban based study.
Strength of our study includes the large number of
pregnant women as well as extensive longitudinal
questionnaires addressing many aspects of health, nu-
trition, hygiene and reproductive behaviour. Bio-
sampling of many biomaterials at close time points
from both, mothers and infants, will enable identifica-
tion of biomarkers and addressing of pathomechan-
isms in future translational experiments. In our study,
we will document timing of ART before, during and
after pregnancy in detail, allowing studying the effects
of foetal exposure to ART at different time points on
birth outcomes and infant developments. Further-
more, our study has a comparative group of HUU in-
fants enrolled from the same community sampled at
the same time. Finally, even though Zimbabwe cur-
rently faces pronounced economic challenges, literacy
is nearly universal. Research participants should
understand study procedures well, and mothers will
be able to document infant health in morbidity diar-
ies and follow the study processes with high
compliance.
Fig. 1 Main Study and sub-studies Flow Diagram. ART: Antiretroviral therapy, BM: Breast milk, Co-infections include hepatitis B virus, hepatitis C
virus, CMV:cytomegalovirus, and intestinal parasites. HEI: HIV exposed and infected, HEU: HIV exposed but uninfected HIV: Human
immunodeficiency virus, HUU: HIV unexposed and uninfected, MIPs: Mother -infant pairs, NCD: Non-communicable diseases and these include
hypertensive disorders, malnutrition and diabetes, STIs: Sexually transmitted infections
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Limitations of our study include the non-
interventional study design. Therefore, any important as-
sociation identified would need to be confirmed by an
interventional study. Further, gestation age estimate is
based on reported last menstrual period that may be as-
sociated with recall bias and complementary use of
ultrasound is missing. Moreover, due to the high preva-
lence of environmental risk factors for infant health re-
lated to poor socio-economic status, some specific risk
factors might not be identified by our study design.
Therefore, there is the possibility of a type II error for
adverse effects of ART with low risk in our cohort due
to a high number of additional risk factors. Finally, all
our research participants reside in a rather homoge-
neous high-density residential area in Harare, Zimbabwe.
Our results will therefore probably apply to similar re-
source limited settings in SSA. However, results from
our cohort might not be generalizable to other more af-
fluent urban environments or rural areas. Caution would
be needed to generalize our results to industrialized
countries.
In summary, we introduce the University of
Zimbabwe birth cohort study, which is following up
600 HIV infected and 600 uninfected mothers and
their infants in a resource limited setting in a high-
density residential areas around Harare. Acquisition
of extensive clinical meta-data and comprehensive
bio-sampling will enable us to answer many questions
important for this study population including the
health of HEU infants. This is important, as future
health and wellbeing in adulthood are influenced by
external environmental insults encountered during the
first couple years of life.
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